Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer

被引：0

作者：

Onoue M. ^{[1
]}

Terada T. ^{[1
]}

Okuda M. ^{[1
]}

Fujimoto K. ^{[2
]}

Doi R. ^{[2
]}

Imamura M. ^{[2
]}

Inui K.-I. ^{[1
]}

机构：

[1] Department of Pharmacy, Kyoto University Hospital, Kyoto University, Sakyo-ku

[2] Dept. of Surg. and Surg. Basic Sci., Graduate School of Medicine, Kyoto University, Kyoto

来源：

International Journal of Clinical Oncology | 2004年 / 9卷 / 3期

关键词：

Cancer chemotherapy; Gemcitabine; Leukopenia; Pancreatic cancer; Surgical resection;

D O I：

10.1007/s10147-004-0393-5

中图分类号：

学科分类号：

摘要：

Background. Gemcitabine hydrochloride (GEM) is one of the most effective chemotherapeutic agents for pancreatic cancer; however, factors affecting GEM-induced leukopenia have not been clarified yet. In the present study, we analyzed the relationship between patients' backgrounds and GEM-induced leukopenia. Methods. Thirty-eight patients with pancreatic cancer were analyzed for correlation between the dose of GEM and the blood leukocyte number. Moreover, we compared leukopenia in resected and non-resected patients. Results. The incidence of grade 3 or 4 leukopenia was 25% in the non-resected patients, whereas equivalent leukopenia was observed in 57% of the resected patients (P = 0.048 by the X2 test). The relative decrease in blood leukocytes induced by GEM administration was more severe in resected patients (41.3 ± 9.9%), as compared to non-resected patients (52.6 ± 16.0%; P = 0.023 by t-test). Conclusion. In the present study, we found that the administration of GEM to patients after surgical resection caused more severe leukopenia, as compared to findings in non-resected patients. These data suggested that more frequent monitoring of the leukocyte count and prolonged intervals between GEM administrations are necessary for resected patients with pancreatic cancer.

引用

页码：174 / 178

页数：4

共 12 条

[1]

Warshaw A.L., Castillo C.F.-D., Pancreatic carcinoma, N Engl J Med, 326, pp. 455-465, (1992)

[2]

Laethem J.-L.V., Demols A., Gay F., Et al., Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: A phase II study, Int J Radiat Oncol Biol Phys, 56, pp. 974-980, (2003)

[3]

Burris III H.A., Moore M.J., Andersen J., Et al., Improvements in survival and clinical benefit with gemcitbine as first-line therapy for patients with advanced pancreas cancer: A randomized trial, J Clin Oncol, 15, pp. 2403-2413, (1997)

[4]

Haller D.G., Chemotherapy for advanced pancreatic cancer, Int J Radiat Oncol Biol Phys, 56, pp. 16-23, (2003)

[5]

Okada S., Ueno H., Okusaka T., Et al., Phase I trial of gemcitabine in patients with advanced pancreatic cancer, Jpn J Clin Oncol, 31, pp. 7-12, (2001)

[6]

Onoue M., Kato T., Terada T., Et al., Pharmaceutical care on pancreatic cancer chemotherapy. Appropriate usage of G-CSF (granulocyte colony-stimulating factor) for gemcitabine-induced leukopenia, Jpn J Pharm Health Care Sci, 28, pp. 391-396, (2003)

[7]

Marty M., Pouillart P., Scholl S., Et al., Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis, N Engl J Med, 322, pp. 816-821, (1990)

[8]

Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in preventation of cisplatin-induced emesis, Lancet, 340, pp. 96-99, (1992)

[9]

Gabrilove J.L., Jakubowski A., Scher H., Et al., Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium, N Engl J Med, 318, pp. 1414-1422, (1988)

[10]

Goncalves A., Viret F., Ciccolini J., Et al., Phase I and pharmacokinetic study of escalating dose of docetaxel administrated with granulocyte colony-stimulating factor support in adult advanced solid tumors, Clin Cancer Res, 9, pp. 102-108, (2003)

← 1 2 →